NO20071946L - Stabile vaeskeformuleringer av plasmid DNA - Google Patents

Stabile vaeskeformuleringer av plasmid DNA

Info

Publication number
NO20071946L
NO20071946L NO20071946A NO20071946A NO20071946L NO 20071946 L NO20071946 L NO 20071946L NO 20071946 A NO20071946 A NO 20071946A NO 20071946 A NO20071946 A NO 20071946A NO 20071946 L NO20071946 L NO 20071946L
Authority
NO
Norway
Prior art keywords
plasmid dna
plasmid
dna
stable
liquid formulations
Prior art date
Application number
NO20071946A
Other languages
English (en)
Inventor
Michel Couder
Francis Blanche
Nicolas Maestrali
Thierry Guillemin
David Gaillac
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/011437 external-priority patent/WO2005026331A2/en
Priority claimed from PCT/EP2005/005213 external-priority patent/WO2005100542A1/en
Application filed by Centelion filed Critical Centelion
Publication of NO20071946L publication Critical patent/NO20071946L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Denne oppfinnelse er relatert til plasmid DNA væskeformuleringer som er stabile og forblir udegradert ved +4 ?C til romtemperatur for lange tidsperioder, og er derfor nyttige for lagring av plasmid DNA som er benyttet i forskning, plasmidbasert terapi, slik som DNA vaksine og genterapi. Den foreliggende oppfinnelse er også relatert til en fremgangsmåte for å konservere plasmid DNA i en stabil form over tid ved +4 ?C til romtemperatur. Den foreliggende oppfinnelse er også relatert til stabile plasmid DNA væskesammensetninger for anvendelse i en fremgangsmåte for å behandle menneskekroppen eller dyrekroppen ved plasmidbasert terapi, slik som DNA vaksinasjon eller genterapi.
NO20071946A 2004-09-17 2007-04-17 Stabile vaeskeformuleringer av plasmid DNA NO20071946L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2004/011437 WO2005026331A2 (en) 2003-09-17 2004-09-17 Method of preparation of pharmaceutically grade plasmid dna
PCT/EP2005/005213 WO2005100542A1 (en) 2004-04-19 2005-04-19 Method for purifying plasmid dna
PCT/EP2005/010881 WO2006029908A1 (en) 2004-09-17 2005-09-19 Stable liquid formulations of plasmid dna

Publications (1)

Publication Number Publication Date
NO20071946L true NO20071946L (no) 2007-05-29

Family

ID=56290732

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071946A NO20071946L (no) 2004-09-17 2007-04-17 Stabile vaeskeformuleringer av plasmid DNA

Country Status (14)

Country Link
EP (1) EP1791945A1 (no)
JP (1) JP2008512997A (no)
KR (1) KR20070058621A (no)
CN (1) CN101040041A (no)
AU (1) AU2005284244A1 (no)
BR (1) BRPI0515553A (no)
CA (1) CA2579340A1 (no)
EA (1) EA011554B1 (no)
IL (1) IL181753A0 (no)
MX (1) MX2007003214A (no)
NO (1) NO20071946L (no)
NZ (1) NZ553914A (no)
TN (1) TNSN07087A1 (no)
WO (1) WO2006029908A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2542385C2 (ru) 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
CN104032005B (zh) * 2014-06-12 2015-11-25 成都中创清科医学检验所有限公司 一种pcr测序中间产物的保存剂及保存方法
JP6462723B2 (ja) * 2014-12-29 2019-01-30 株式会社ボナック 核酸分子を安定に含有する組成物
RU2612497C2 (ru) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
RU2628087C1 (ru) * 2016-09-01 2017-08-14 Игорь Валериевич Корниенко Композиция с противомикробным действием для хранения днк или днк-содержащих препаратов (варианты) и её применение
CN106554956A (zh) * 2016-12-07 2017-04-05 安徽智飞龙科马生物制药有限公司 一种产业化制备BCG‑CpG‑DNA的方法
CN110869501B (zh) * 2017-08-01 2023-08-18 深圳华大智造科技股份有限公司 一种高效的内切酶缓冲液体系
AU2018321760A1 (en) * 2017-08-25 2020-02-27 Zoetis Services Llc A nucleic acid probe, a method of immobilizing the nucleic acid to a solid support using UV light, a solid support comprising an immobilized nucleic acid probes, and a test device comprising a solid support
CN111433584B (zh) * 2017-11-22 2023-10-31 拜克门寇尔特公司 稀释剂制备模块和单元
EP3844301A1 (en) * 2018-08-30 2021-07-07 GlaxoSmithKline Intellectual Property Development Ltd Methods of detecting nucleic acid
CN111718961B (zh) * 2019-07-03 2022-02-08 华大青兰生物科技(无锡)有限公司 一种用质粒转化细菌的方法
CN115404232A (zh) * 2021-05-10 2022-11-29 艾棣维欣(苏州)生物制品有限公司 用于提取细菌中质粒dna的方法
WO2023182614A1 (ko) * 2022-03-24 2023-09-28 주식회사 헬릭스미스 플라스미드 dna를 포함하는 액체제형 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
FR2773818B1 (fr) * 1998-01-21 2000-02-18 Pasteur Merieux Serums Vacc Procede et dispositif de lyse de bacteries
WO2001043693A2 (en) * 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef

Also Published As

Publication number Publication date
CA2579340A1 (en) 2006-03-23
WO2006029908A1 (en) 2006-03-23
BRPI0515553A (pt) 2008-07-29
EA011554B1 (ru) 2009-04-28
AU2005284244A1 (en) 2006-03-23
MX2007003214A (es) 2007-10-11
EA200700656A1 (ru) 2007-10-26
CN101040041A (zh) 2007-09-19
EP1791945A1 (en) 2007-06-06
JP2008512997A (ja) 2008-05-01
NZ553914A (en) 2009-11-27
KR20070058621A (ko) 2007-06-08
IL181753A0 (en) 2007-07-04
TNSN07087A1 (en) 2008-06-02

Similar Documents

Publication Publication Date Title
NO20071946L (no) Stabile vaeskeformuleringer av plasmid DNA
BR0210839A (pt) Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico
NO20073814L (no) GLP-1-agonister, sammensetninger, fremgangsmater og anvendelser
NO20055977L (no) Nye benzimidazolderivater
NO20064584L (no) Tetrahydropyridoindolderivater
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
PA8609201A1 (es) Piridinonas sustituidas
BR112015005674A2 (pt) variantes e métodos de uso de hppd
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
MX2007004841A (es) Triazoles utiles como inhibidores de proteinas cinasas.
DK1758860T3 (da) Mættede og umættede 3-pyridylbenzocykloalkylmethylaminer til behandling af smerter, depressioner og angsttilstande
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
EA200700613A1 (ru) Метаболически активные микроорганизмы и способы их получения
NO20082684L (no) F-, G-, H-, I- og K-krystallformer av imatinibmesylat
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
NO20005411L (no) Antipicornavirusforbindelser, deres fremstilling og anvendelse
NO20061033L (no) Sammensetninger og fremgangsmater for levering av biologiske aktive midler
NO20061138L (no) Gjaercellevegger for behandling eller forebygging av hyperglukemi eller for a stabilisere glukemi
UA87494C2 (en) Azaindoles useful as inhibitors of jak and other protein kinases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application